688520.SH
Sinocelltech Group Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 36.39
−3.96%Sep 13, 2026, 11:45 UTC
Four shareholders of Sinocelltech plan to reduce their combined stake by no more than 0.94%.
Source:Sep 13, 2026, 07:32 UTC
Four shareholder and employee stock ownership platforms of Sino Biological announced plans to collectively reduce their stake in the company by no more than 0.94% of total shares between October 13, 2026 and January 12, 2027.
Source:Aug 28, 2026, 09:17 UTC
SinoCell Technologies reported a net loss of 366 million yuan for the first half of 2026, compared with a loss of 33.77 million yuan in the same period of 2025.
Source:Aug 19, 2026, 09:10 UTC
Sinocelltech's controlled subsidiary Sinocelltech Engineering received approval from China's National Medical Products Administration to conduct clinical trials for its SCTB10 injection in hemophilia A.